Bisphosphonate and osteonecrosis of the jaw: The oral surgeon's perspective

European Journal of Inflammation

Volumn 10, Issue 1, 2012, Pages 11-23

  Pompa, Giorgio ^a   Bignozzi, I ^a   Cristalli, M P ^a   Quaranta, A ^b   Di Carlo, Stefano ^a   Annibali, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Bisphosphonates; Jaw bone; Osteonecrosis; Pathogenesis; Prevention osteonecrosis of the jaw; Risk factors

Indexed keywords

ADENOSINE TRIPHOSPHATE; BISPHOSPHONIC ACID DERIVATIVE; CYTOCHROME C; GELATINASE A; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; RAC PROTEIN; RHO FACTOR; VASCULOTROPIN RECEPTOR 2; ZOLEDRONIC ACID;

ANTIBIOTIC THERAPY; APOPTOSIS; BONE DESTRUCTION; BONE METASTASIS; BONE MINERAL; BONE REMODELING; BONE TURNOVER; BREAST CANCER; CELL DEATH; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; DISEASE SEVERITY; DNA FRAGMENTATION; GENETIC POLYMORPHISM; HUMAN; INFORMATION DISSEMINATION; ISOPRENYLATION; JAW OSTEONECROSIS; LOW LEVEL LASER THERAPY; MEMBRANE DEPOLARIZATION; MITOCHONDRIAL MEMBRANE; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; OZONE THERAPY; PERIODONTAL DISEASE; PRENYLATION; QUALITY OF LIFE; REVIEW; RISK FACTOR; TOOTH EXTRACTION;

EID: 84861665532     PISSN: 1721727X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1721727X1201000102     Document Type: Review

References (40)

1. Marx RE, Stern DS. Biopsy principles and techniques. Oral and Maxillofacial Pathology: A Rationale for Diagnosis and Treatment. 2002. Chicago: Quintessence: 36-38
2. Dearden WF. Fragilitas ossium amongst workers in Lucifer match factories. Br Med J 1899; 2:270-1.
3. Russell RG. Bisphosphonates: from bench to bedside. Ann NY Acad Sci 2006; 1068:367-401. (Pubitemid 43824169)
4. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res 2006; 12:6222s-6230s. (Pubitemid 44703794)
5. Frith JC, Mönkkönen J, Blackburn GM, Russell RG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 1997; 12:1358-67. (Pubitemid 27375378)
6. Ghoneima AA, Allam ES, Zunt SL, Windsor LJ. Bisphosphonates treatment and orthodontic considerations. Orthod Craniofac Res 2010; 13:1-10.
7. Pavlos NJ, Xu J, Riedel D, et al. Rab3D regulates a novel vesicular trafficking pathway that is required for osteoclastic bone resorption. Mol Cell Biol 2005; 25:5253-69. (Pubitemid 40781122)
8. Fujita H, Utsumi T, Muranaka S, Ogino T, Yano H, Akiyama J, Yasuda T, Utsumi K. Involvement of Ras/extracellular signal-regulated kinase, but not Akt pathway in risedronate-induced apoptosis of U937 cells and its suppression by cytochalasin B. Biochem Pharmacol 2005; 69:1773-84. (Pubitemid 40780077)
9. Van Beek ER, Löwik CW, Papapoulos SE. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors. Bone 2002; 30:64-70. (Pubitemid 34044302)
10. Iguchi T, Miyakawa Y, Yamamoto K, Kizaki M, Ikeda Y Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalonate pathway. Cell Signal 2003; 15:719-27. (Pubitemid 36556076)
11. Tanaka T, Tatsuno I, Uchida D, et al. Geranylgeranylpyrophosphate, an isoprenoid of mevalonate cascade, is a critical compound for rat primary cultured cortical neurons to protect the cell death induced by 3-hydroxy-3-methylglutaryl-CoA reductase inhibition. J Neurosci 2000; 20:2852-9. (Pubitemid 30220310)
12. Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. Eur J Pharmacol 2007; 570:27-37. (Pubitemid 47247687)
13. Virtanen SS, Väänänen HK, Härkönen PL, Lakkakorpi PT. Alendronate inhibits invasion of PC-3 prostate cancer cells by affecting the mevalonate pathway. Cancer Res 2002; 62:2708-14. (Pubitemid 34462756)
14. Suri S, Mönkkönen J, Taskinen M, Pesonen J, Blank MA, Phipps RJ, Rogers MJ. Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: a model of bisphosphonate-induced gastrointestinal toxicity. Bone 2001; 29:336-43. (Pubitemid 32930060)
15. Scavelli C, Di Pietro G, Cirulli T, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007; 6:3256-62.
16. Santini D, Vincenzi B, Galluzzo S, et al. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res 2007; 13:4482-6. (Pubitemid 47219717)
17. Giraudo E, Inoue M, Hanahan D. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J Clin Invest 2004; 114:623-33. (Pubitemid 39578752)
18. Green JR, Müller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994; 9:745-51. (Pubitemid 24130477)
19. Wang J, Goodger NM, Pogrel MA. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 2003; 61:1104-7. (Pubitemid 37064708)
20. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003; 61:1115-17. (Pubitemid 37064711)
21. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases.J Oral Maxillofac Surg 2004; 62:527-34. (Pubitemid 38542516)
22. Filleul O, Crompot E, Saussez S. Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 2010; 136:1117-24.
23. Bertoldo F, Santini D, Lo Cascio V. Bisphosphonates and osteomyelitis of the jaw: a pathogenic puzzle. Nat Clin Pract Oncol 2007; 4:711-21. (Pubitemid 350187006)
24. Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-11.
25. Senel FC, Duman MK, Muci E, Cankaya M, Pampu AA, Ersoz S, Gunhan O. Jaw bone changes in rats after treatment with zoledronate and Pamidronate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109:385-91.
26. Lehrer S, Montazem A, Ramanathan L, Pessin-Minsley M, Pfail J, Stock RG, Kogan R. Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene. J Oral Maxillofac Surg 2009; 67:159-6
27. Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW, Sedghizadeh PP. The role of microbial biofilms in osteonecrosis of the jaw associated with bisphosphonate therapy. Curr Osteoporos Rep 2010; 8:40-48.
28. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007; 65:415-23. (Pubitemid 46343586)
29. Khosla S, Burr D, Cauley J, et al; American Society for Bone and Mineral Research. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research.J Bone Miner Res 2007; 22:1479-91. (Pubitemid 351229318)
30. Migliorati CA, Siegel MA, Elting LS. Bisphosphonate-associated osteonecrosis: a longterm complication of bisphosphonate treatment. Lancet Oncol 2006; 7(6):508-54.
31. Mehrotra B, Ruggiero S. Bisphosphonate complications including osteonecrosis of the jaw. Hematology Am Soc Hematol Educ Program 2006; 515:356-60.
32. Chiandussi S, Biasotto M, Dore F, Cavalli F, Cova MA, Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol. 2006; 35:236-43. (Pubitemid 44076879)
33. Ruggiero S, Gralow J, Marx RE, et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Pract 2006; 2:7-14.
34. Nocini PF, Saia G, Bettini G, Ragazzo M, Blandamura S, Chiarini L, Bedogni. A Vascularized fibula flap reconstruction of the mandible in bisphosphonate-related osteonecrosis. Eur J Surg Oncol 2009; 35:373-9.
35. Pastore D, Greco M, Petragallo VA, Passarella S. Increase in <-H+/e- ratio of the cytochrome c oxidase reaction in mitochondria irradiated with helium-neon laser. Biochem Mol Biol Int 1994; 34:817-26. (Pubitemid 24347425)
36. Karu T, Pyatibrat L, Kalendo G. Irradiation with HeNe laser increases ATP level in cells cultivated in vitro. J Photochem Photobiol B 1995; 27:219-23.
37. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G. Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 2007; 18:1071-5. (Pubitemid 47524914)
38. Vescovi P, Merigo E, Manfredi M, Meleti M, Fornaini C, Bonanini M, Rocca JP, Nammour S. Nd:YAG laser biostimulation in the treatment of bisphosphonate-associated osteonecrosis of the jaw: clinical experience in 28 cases. Photomed Laser Surg 2008; 26:37-46 (Pubitemid 351206155)
39. Scoletta M, Arduino PG, Reggio L, Dalmasso P, Mozzati M. Effect of low-level laser irradiation on bisphosphonate-induced osteonecrosis of the jaws: preliminary results of a prospective study. Photomed Laser Surg 2010; 28:179-84.
40. Curi MM, Cossolin GS, Koga DH, Araújo SR, Feher O, dos Santos MO, Zardetto C. Treatment of avascular osteonecrosis of the mandible in cancer patients with a history of bisphosphonate therapy by combining bone resection and autologous platelet-rich plasma: Report of 3 cases. J Oral Maxillofac Surg 2007; 65:349-55. (Pubitemid 46131421)